Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Elisa Lucchini

10PUBLICATIONS

106CO-AUTHORS

Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|Dec 30, 2025

Secondary Genetic Events and Their Relationship to <i>TP53</i> Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL).

Maria Elena Carazzolo, Francesca Maria Quaglia, Antonino Aparo

|Sep 12, 2025

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Emanuele Zucca, Luca Ceriani, Giovannino Ciccone

|Aug 26, 2025

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Elisa Lucchini, Nicola Vianelli, Ugo Consoli

|Mar 16, 2025

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.

David J Kuter, Waleed Ghanima, Nichola Cooper

|Jan 14, 2025

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.

Simone Ragaini, Anna Galli, Elisa Genuardi

|Aug 19, 2024

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Maurizio Martelli, Luca Ceriani, Giovannino Ciccone

Pageof 2

Frequent Collaborators

4 joint publications

Monica Balzarotti

2 joint publications

Francesca Palandri

2 joint publications

Luca Arcaini

2 joint publications

Elisa Genuardi

2 joint publications

Federica Cavallo

2 joint publications

Simone Ferrero

2 joint publications

Andrés J M Ferreri

2 joint publications

Alice Di Rocco

2 joint publications

Francesco Zaja

2 joint publications

Monica Carpenedo

Frequent Collaborators

4 joint publications

Monica Balzarotti

2 joint publications

Francesca Palandri

2 joint publications

Luca Arcaini

2 joint publications

Elisa Genuardi

Top Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on : Jun 13, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on : Feb 12, 2017

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on : Jul 31, 2016

See more related videos

Top Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on : Jun 13, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on : Feb 12, 2017

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on : Jul 31, 2016

See more related videos